184 related articles for article (PubMed ID: 34753779)
1. Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia.
Pollyea DA; Barrett J; DiNardo CD; Michaelis LC; Roboz GJ; Le RQ; Norsworthy KJ; de Claro RA; Theoret MR; Pazdur R
Clin Cancer Res; 2022 Mar; 28(5):816-820. PubMed ID: 34753779
[TBL] [Abstract][Full Text] [Related]
2. Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
Fangusaro J; Avery RA; Fisher MJ; Packer RJ; Walsh KS; Schouten-van Meeteren A; Karres D; Bradford D; Bhatnagar V; Singh H; Kluetz PG; Donoghue M; Duke ES
Clin Cancer Res; 2024 Jun; 30(11):2303-2308. PubMed ID: 38358393
[TBL] [Abstract][Full Text] [Related]
3. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206
[TBL] [Abstract][Full Text] [Related]
4. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
5. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
[TBL] [Abstract][Full Text] [Related]
6. A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
Patel SA; Gerber JM
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):277-288. PubMed ID: 32113891
[TBL] [Abstract][Full Text] [Related]
7. Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.
Seo J; Smith BD; Estey E; Voyard E; O' Donoghue B; Bridges JFP
Curr Med Res Opin; 2018 Dec; 34(12):2031-2039. PubMed ID: 29565196
[TBL] [Abstract][Full Text] [Related]
8. Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV; Abedin SM; Atallah E
Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
[TBL] [Abstract][Full Text] [Related]
9. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
10. Identifying effective drug combinations for patients with acute myeloid leukemia.
Yilmaz M; Kadia T; Ravandi F
Expert Rev Anticancer Ther; 2020 Jul; 20(7):591-601. PubMed ID: 32552126
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial risk in leukemia: Biomarkers and trial design.
Li AJ; Dhanraj JP; Lopes G; Parker JL
Hematol Oncol; 2021 Feb; 39(1):105-113. PubMed ID: 33078436
[TBL] [Abstract][Full Text] [Related]
12. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
13. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
14. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
15. Acute Myeloid Leukemia: How Do We Measure Success?
Sasine JP; Schiller GJ
Curr Hematol Malig Rep; 2016 Dec; 11(6):528-536. PubMed ID: 27604228
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
17. First Approved Kinase Inhibitor for AML.
Rasko JEJ; Hughes TP
Cell; 2017 Nov; 171(5):981. PubMed ID: 29149610
[TBL] [Abstract][Full Text] [Related]
18. Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
Tran AA; Miljković M; Prasad V
Leuk Res; 2020 Sep; 96():106420. PubMed ID: 32712431
[TBL] [Abstract][Full Text] [Related]
19. Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development.
Gao W; Liu J; Shtylla B; Venkatakrishnan K; Yin D; Shah M; Nicholas T; Cao Y
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):691-709. PubMed ID: 37969061
[TBL] [Abstract][Full Text] [Related]
20. Midostaurin Gets FDA Nod for AML.
Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
